Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced a preview of business updates. Management will be attending the 13th Annual LifeSci Partners Corporate Access Event in San Francisco from January 8-10 and will be available to discuss updates. This event takes place during the week of the annual J.P. Morgan Health Care Conference.
Trevi to attend 13th Annual LifeSci Partners Corporate Access Event and provides business updates
"Our team is very excited about Trevi's outlook for 2024 having initiated two clinical trials in chronic cough and the Human Abuse Potential study late in 2023," said Jennifer Good, President and CEO of Trevi Therapeutics. "We look forward to advancing the development of Haduvio through both our Phase 2b CORAL dose ranging trial for chronic cough in IPF and our Phase 2a RIVER proof-of-concept trial in refractory chronic cough, as well as completing the Human Abuse Potential study. We believe Haduvio's ability to work both centrally in the brain and peripherally in the lungs has the potential for a synergistic antitussive effect to treat chronic cough that could enable use among patients with both moderate and severe cough frequencies. We look forward to a data-rich year as we progress through this next critical stage of development."
Key Business Updates
Posted In: TRVI